新药周观点：口服GLP-1药物减重数据更新，国内多家企业积极布局

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical sector [8]. Core Insights - The report highlights significant advancements in oral GLP-1 drugs, with AstraZeneca's AZD5004 and Viking Therapeutics' VK2735 showing promising weight loss results of 5.8% and 8.2% respectively after four weeks of treatment [2][24]. - Multiple domestic companies are actively developing oral GLP-1 drugs, with several products entering clinical development stages [2][28]. - A total of 9 new drugs or new indications were approved for market entry this week, along with 1 new drug receiving IND approval and 40 new drugs accepted for IND [29][30]. Summary by Sections New Drug Market Review - From November 4 to November 8, the top five companies in the new drug sector by stock price increase were: Kexing Pharmaceutical (57.83%), Yanhong Pharmaceutical (18.36%), Laika Pharmaceutical (17.20%), Yunding Xinyao (17.10%), and Heyu (14.15%). The top five companies with stock price declines were: Kedi (-19.36%), Donghui Pharmaceutical (-9.14%), Youzhiyou Biological (-7.90%), Beihai Kangcheng (-7.69%), and Yongtai Biological (-7.69%) [1][21]. Key Analysis of New Drug Industry - Recent data on oral GLP-1 drugs, including AstraZeneca's AZD5004 and Viking Therapeutics' VK2735, indicate effective weight loss outcomes, with reductions of 5.8% and 8.2% respectively after four weeks [2][24]. - Domestic companies are progressing in the development of oral GLP-1 drugs, with several products in various clinical stages, including Eli Lilly's Orforglipron in Phase 3 and products from Heng Rui Pharmaceutical and Huadong Medicine in Phase 2 [2][28]. New Drug Approval & Acceptance - This week, 9 new drugs or new indications were approved for market entry, 1 new drug received IND approval, and 40 new drugs were accepted for IND [29][30]. Domestic New Drug Industry Focus - Key highlights include the priority review application for Ascentage Pharma's Bcl-2 selective inhibitor Lisaftoclax, clinical data presentations by Kexing Pharmaceutical at the ASH annual meeting, and the establishment of a new drug development company by Valiant Biotech in collaboration with Aditum Bio [4][36].